CatalYm GmbH has closed a Series C financing round, raising €50 million to support development of a therapy directed at the immune system for cancer. The Munich, Germany company has a candidate monoclonal antibody engineered to neutralise the tumour-produced growth differentiation factor-15 (GDF-15). GDF-15 acts as a regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumour tissue.
